{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:40:39Z","timestamp":1747204839195,"version":"3.40.5"},"posted":{"date-parts":[[2023,7,18]]},"group-title":"In Review","reference-count":130,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,7,1]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background<\/bold> Cognitive decline in Alzheimer\u2019s disease (AD) is associated with prion-like tau propagation between neurons along synaptically connected networks, in part via extracellular vesicles (EV). EV biogenesis is triggered by ceramide enrichment at the plasma membrane from neutral sphingomyelinase2(nSMase2)-mediated cleavage of sphingomyelin. We report, for the first time, that tau expression triggers an elevation in brain ceramides and nSMase2 activity.<bold>Methods<\/bold> To determine the therapeutic benefit of inhibiting this elevation, we evaluated the efficacy of PDDC, the first potent, selective, orally bioavailable, and brain-penetrable nSMase2 inhibitor, in the PS19 tau transgenic AD murine model. Changes in brain ceramide and sphingomyelin levels, Tau content, histopathology, and nSMase2 target engagement were monitored, as well as changes in the number of brain-derived EVs in plasma and their Tau content. Additionally, we evaluated the ability of PDDC to impede tau propagation in a murine model where an adeno-associated virus(AAV) encoding for P301L\/S320F double mutant human tau was stereotaxically-injected unilaterally into the hippocampus and the contralateral transfer to the dentate gyrus was monitored.<bold>Results<\/bold> Similar to human AD, PS19 mice exhibited increased brain ceramides and nSMase2 activity; both were completely normalized by PDDC treatment. PS19 mice exhibited elevated tau immunostaining, thinning of hippocampal neuronal cell layers, increased mossy fiber synaptophysin immunostaining, and glial activation, all pathologic features of human AD. PDDC treatment significantly attenuated these aberrant changes. Mouse plasma isolated from PDDC-treated PS19 mice exhibited reduced levels of neuron- and microglia-derived EVs, the former carrying lower phosphorylated Tau(pTau) levels, compared to untreated mice. In the AAV tau propagation model, PDDC normalized the tau-induced increase in brain ceramides and significantly decreased tau spreading to the contralateral side.<bold>Conclusions<\/bold> PDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity leading to the slowing of tau spread in AD mice.<\/p>","DOI":"10.21203\/rs.3.rs-3131295\/v1","type":"posted-content","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T15:49:57Z","timestamp":1689695397000},"source":"Crossref","is-referenced-by-count":1,"title":["Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in murine Alzheimer\u2019s disease"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-547X","authenticated-orcid":false,"given":"Carolyn","family":"Tallon","sequence":"first","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J","family":"Bell","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhinee M","family":"Malvankar","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragney","family":"Deme","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Nogueras-Ortiz","sequence":"additional","affiliation":[{"name":"National Institute on Aging Laboratory of Clinical Investigation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erden","family":"Eren","sequence":"additional","affiliation":[{"name":"National Institute on Aging Laboratory of Clinical Investigation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit G","family":"Thomas","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen R","family":"Hollinger","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arindom","family":"Pal","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Mustapic","sequence":"additional","affiliation":[{"name":"National Institute on Aging Laboratory of Clinical Investigation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meixiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaleem","family":"Coleman","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawnjerae R","family":"Joe","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman J","family":"Haughey","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-3118","authenticated-orcid":false,"given":"Dimitrios","family":"Kapogiannis","sequence":"additional","affiliation":[{"name":"National Institute on Aging Laboratory of Clinical Investigation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-4157","authenticated-orcid":false,"given":"Barbara S","family":"Slusher","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"author":"Biogen","key":"ref1","unstructured":"Biogen, Biogen and Eisai Announce Design of ADUHELM ICARE AD-US. Study, the First Real-World Observational Phase 4 Study in Alzheimer\u2019s Disease at AAIC 2021. (2021)."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos KI","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. Ageing Res Rev. 2021;68:101339.","journal-title":"Ageing Res Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak H","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Jr., O. Hansson, Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele R","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jogi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR. Jr., O. Hansson, Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137.","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.febslet.2011.11.022","article-title":"Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles","volume":"586","author":"Simon D","year":"2012","unstructured":"Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012;586:47\u201354.","journal-title":"FEBS Lett"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","article-title":"Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review","volume":"76","author":"Gibbons GS","year":"2019","unstructured":"Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review. JAMA Neurol. 2019;76:101\u20138.","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acn3.176","article-title":"Anti-tau antibody reduces insoluble tau and decreases brain atrophy","volume":"2","author":"Yanamandra K","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2:278\u201388.","journal-title":"Ann Clin Transl Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","article-title":"Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating","volume":"20","author":"Mullard A","year":"2021","unstructured":"Mullard A. Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov. 2021;20:3\u20135.","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1673-5374.340409","article-title":"Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-beta story","volume":"18","author":"Imbimbo BP","year":"2023","unstructured":"Imbimbo BP, Balducci C, Ippati S, Watling M. Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-beta story. Neural Regen Res. 2023;18:117\u20138.","journal-title":"Neural Regen Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1074\/jbc.M111.277061","article-title":"Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease","volume":"287","author":"Saman S","year":"2012","unstructured":"Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287:3842\u20139.","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/brain\/awaa376","article-title":"Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons","volume":"144","author":"Ruan Z","year":"2021","unstructured":"Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N, Takamatsu-Yukawa K, Hu J, Wang Y, Hersh S, Ericsson M, Gorantla S, Gendelman HE, Kayed R, Ikezu S, Luebke JI, Ikezu T. Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain. 2021;144:288\u2013309.","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic K","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B, Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244\u20137.","journal-title":"Science"},{"key":"ref13","article-title":"Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases","author":"Tallon C","year":"2021","unstructured":"Tallon C, Hollinger KR, Pal A, Bell BJ, Rais R, Tsukamoto T, Witwer KW, Haughey NJ, Slusher BS. Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. Drug Discovery Today, (2021).","journal-title":"Drug Discovery Today"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/jnr.22438","article-title":"Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice","volume":"88","author":"Tabatadze N","year":"2010","unstructured":"Tabatadze N, Savonenko A, Song H, Bandaru VV, Chu M, Haughey NJ. Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res. 2010;88:2940\u201351.","journal-title":"J Neurosci Res"},{"year":"2022","author":"Tallon C","key":"ref15","unstructured":"Tallon C, Bell BJ, Sharma A, Pal A, Malvankar MM, Thomas AG, Yoo SW, Hollinger KR, Coleman K, Wilkinson EL, Kannan S, Haughey NJ, Kannan RM, Rais R. B. S. Slusher, Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice. Pharmaceutics 14, (2022)."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","article-title":"Depletion of microglia and inhibition of exosome synthesis halt tau propagation","volume":"18","author":"Asai H","year":"2015","unstructured":"Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kugler S, Ikezu T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584\u201393.","journal-title":"Nat Neurosci"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.0c00311","article-title":"Dual Neutral Sphingomyelinase-2\/Acetylcholinesterase Inhibitors for the treatment of Alzheimer\u2019s disease","author":"Bilousova T","year":"2020","unstructured":"Bilousova T, Simmons BJ, Knapp RR, Elias CJ, Campagna J, Melnik M, Chandra S, Focht S, Zhu C, Vadivel K, Jagodzinska B, Cohn W, Spilman P, Gylys KH, Garg NK, John V. Dual Neutral Sphingomyelinase-2\/Acetylcholinesterase Inhibitors for the treatment of Alzheimer\u2019s disease. ACS Chem Biol, (2020).","journal-title":"ACS Chem Biol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1111\/bph.14789","article-title":"A novel and potent brain penetrant inhibitor of extracellular vesicle release","volume":"176","author":"Rojas C","year":"2019","unstructured":"Rojas C, Sala M, Thomas AG, Datta Chaudhuri A, Yoo SW, Li Z, Dash RP, Rais R, Haughey NJ, Nencka R, Slusher B. A novel and potent brain penetrant inhibitor of extracellular vesicle release. Br J Pharmacol. 2019;176:3857\u201370.","journal-title":"Br J Pharmacol"},{"key":"ref19","article-title":"Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer disease","author":"Sala M","year":"2020","unstructured":"Sala M, Hollinger KR, Thomas AG, Dash RP, Tallon C, Veeravalli V, Lovell L, K\u00f6gler M, Hrebabecky H, Prochazkova E, Nesuta O, Donoghue A, Lam J, Rais R, Rojas C, Slusher BS, Nencka R. Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer disease. J Med Chem, (2020).","journal-title":"J Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-2011-111202","article-title":"Duerksen-Hughes, Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases","volume":"29","author":"Filippov V","year":"2012","unstructured":"Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, Yang J. Duerksen-Hughes, Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis. 2012;29:537\u201347.","journal-title":"J Alzheimers Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-200964","article-title":"Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia","volume":"81","author":"Teitsdottir UD","year":"2021","unstructured":"Teitsdottir UD, Halldorsson S, Rolfsson O, Lund SH, Jonsdottir MK, Snaedal J, Petersen PH. Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. J Alzheimers Dis. 2021;81:231\u201344.","journal-title":"J Alzheimers Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jalz.2010.03.014","article-title":"Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss","volume":"6","author":"Mielke MM","year":"2010","unstructured":"Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010;6:378\u201385.","journal-title":"Alzheimers Dement"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3233\/JAD-160925","article-title":"The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging","volume":"60","author":"Mielke MM","year":"2017","unstructured":"Mielke MM, Haughey NJ, Han D, An Y, Bandaru VVR, Lyketsos CG, Ferrucci L, Resnick SM. The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. J Alzheimers Dis. 2017;60:819\u201328.","journal-title":"J Alzheimers Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.neuroscience.2004.08.056","article-title":"Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis","volume":"130","author":"Satoi H","year":"2005","unstructured":"Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M, Oka N, Akiguchi I, Furuya S, Hirabayashi Y, Okazaki T. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience. 2005;130:657\u201366.","journal-title":"Neuroscience"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.10312","article-title":"Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis","volume":"52","author":"Cutler RG","year":"2002","unstructured":"Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52:448\u201357.","journal-title":"Ann Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry RD","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572\u201380.","journal-title":"Ann Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","article-title":"Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease","volume":"344","author":"West MJ","year":"1994","unstructured":"West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. The Lancet. 1994;344:769\u201372.","journal-title":"The Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/STROKEAHA.111.636498","article-title":"Hippocampal Neuronal Atrophy and Cognitive Function in Delayed Poststroke and Aging-Related Dementias","volume":"43","author":"Gemmell E","year":"2012","unstructured":"Gemmell E, Bosomworth H, Allan L, Hall R, Khundakar A, Oakley AE, Deramecourt V, Polvikoski TM, O'Brien JT, Kalaria RN. Hippocampal Neuronal Atrophy and Cognitive Function in Delayed Poststroke and Aging-Related Dementias. Stroke. 2012;43:808\u201314.","journal-title":"Stroke"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neurobiolaging.2021.09.006","article-title":"Lasagna-Reeves, Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy","volume":"109","author":"Patel H","year":"2022","unstructured":"Patel H, Martinez P, Perkins A, Taylor X, Jury N, McKinzie D. Lasagna-Reeves, Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol Aging. 2022;109:52\u201363.","journal-title":"Neurobiol Aging"},{"year":"2013","author":"Simon MM","key":"ref30","unstructured":"Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, Sorg T, Wong K, Bedu E, Cartwright EJ, Dacquin R, Djebali S, Estabel J, Graw J, Ingham NJ, Jackson IJ, Lengeling A, Mandillo S, Marvel J, Meziane H, Preitner F, Puk O, Roux M, Adams DJ, Atkins S, Ayadi A, Becker L, Blake A, Brooker D, Cater H, Champy MF, Combe R, Danecek P, di Fenza A, Gates H, Gerdin AK, Golini E, Hancock JM, Hans W, H\u00f6lter SM, Hough T, Jurdic P, Keane TM, Morgan H, M\u00fcller W, Neff F, Nicholson G, Pasche B, Roberson LA, Rozman J, Sanderson M, Santos L, Selloum M, Shannon C, Southwell A, Tocchini-Valentini GP, Vancollie VE, Westerberg H, Wurst W, Zi M, Yalcin B, Ramirez-Solis R, Steel KP, Mallon AM, de Angelis MH, Herault Y, Brown SD. A comparative phenotypic and genomic analysis of C57BL\/6J and C57BL\/6N mouse strains. Genome biology 14, R82 (2013)."},{"key":"ref31","first-page":"375","article-title":"Hrab\u011b de Angelis, Clinical Chemistry Reference Intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ Mice (Mus musculus)","volume":"55","author":"Otto GP","year":"2016","unstructured":"Otto GP, Rathkolb B, Oestereicher MA, Lengger CJ, Moerth C, Micklich K, Fuchs H, Gailus-Durner V, Wolf E. Hrab\u011b de Angelis, Clinical Chemistry Reference Intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ Mice (Mus musculus). J Am Association Lab Anim Science: JAALAS. 2016;55:375\u201386.","journal-title":"J Am Association Lab Anim Science: JAALAS"},{"key":"ref32","unstructured":"T. J. Laboratory."},{"key":"ref33","unstructured":"I. Charles River Larboratories International. (2019)."},{"key":"ref34","unstructured":"I. Taconic Biosciences. (2011)."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"114796","DOI":"10.1016\/j.bcp.2021.114796","article-title":"Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury","author":"Tallon C","year":"2021","unstructured":"Tallon C, Picciolini S, Yoo S-W, Thomas AG, Pal A, Alt J, Carlomagno C, Gualerzi A, Rais R, Haughey NJ, Bedoni M, Slusher BS. Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury. Biochem Pharmacol, 114796 (2021).","journal-title":"Biochem Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama Y","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337\u201351.","journal-title":"Neuron"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","article-title":"Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study","volume":"11","author":"Fiandaca MS","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 2015;11:600\u2013607e601.","journal-title":"Alzheimers Dement"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2462","article-title":"Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of AgingAssociation of Extracellular Vesicle Biomarkers With Alzheimer DiseaseAssociation of Extracellular Vesicle Biomarkers With Alzheimer Disease","author":"Kapogiannis D","year":"2019","unstructured":"Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, Tran J, Lazaropoulos MP, Chawla S, Gulyani S, Eitan E, An Y, Huang C-W, Oh ES, Lyketsos CG, Resnick SM, Goetzl EJ, Ferrucci L. Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of AgingAssociation of Extracellular Vesicle Biomarkers With Alzheimer DiseaseAssociation of Extracellular Vesicle Biomarkers With Alzheimer Disease. JAMA Neurol, (2019).","journal-title":"JAMA Neurol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/hmg\/ddz151","article-title":"Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy","volume":"28","author":"Koller EJ","year":"2019","unstructured":"Koller EJ, De La Cruz EG, Machula T, Ibanez KR, Lin W-L, Williams T, Riffe CJ, Ryu D, Strang KH, Liu X, Janus C, Golde TE, Dickson D, Giasson BI, Chakrabarty P. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Hum Mol Genet. 2019;28:3255\u201369.","journal-title":"Hum Mol Genet"},{"key":"ref40","article-title":"Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer\u2019s Disease","author":"Bell BJ","year":"2020","unstructured":"Bell BJ, Malvankar MM, Tallon C, Slusher BS. Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer\u2019s Disease. ACS Chem Neurosci, (2020).","journal-title":"ACS Chem Neurosci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes","volume":"319","author":"Trajkovic K","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Br\u00fcgger B, Simons M. Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes. Science. 2008;319:1244\u20137.","journal-title":"Science"},{"year":"2022","author":"Chowdhury MR","key":"ref42","unstructured":"Chowdhury MR, Jin HK, Bae JS. Diverse Roles of Ceramide in the Progression and Pathogenesis of Alzheimer's Disease. Biomedicines 10, (2022)."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","article-title":"Jr., Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia","volume":"141","author":"Lowe VJ","year":"2018","unstructured":"Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, Josephs KA, Fang P, Pandey MK, Murray ME, Kantarci K, Jones DT, Vemuri P, Graff-Radford J, Schwarz CG, Machulda MM, Mielke MM, Roberts RO, Knopman DS, Petersen RC, Jack CR. Jr., Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain. 2018;141:271\u201387.","journal-title":"Brain"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele R","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"ref45","unstructured":"Science Advances 7, eabh1448 (2021)."},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos SL","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, Miller TM. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 9, (2017).","journal-title":"Sci Transl Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1073\/pnas.1710311114","article-title":"TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy","volume":"114","author":"Leyns CEG","year":"2017","unstructured":"Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114:11524\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1172\/JCI138179","article-title":"Impact of TREM2R47H variant on tau pathology\u2013induced gliosis and neurodegeneration","volume":"130","author":"Gratuze M","year":"2020","unstructured":"Gratuze M, Leyns CEG, Sauerbeck AD, St-Pierre M-K, Xiong M, Kim N, Serrano JR, Tremblay M-\u00c8, Kummer TT, Colonna M, Ulrich JD, Holtzman DM. Impact of TREM2R47H variant on tau pathology\u2013induced gliosis and neurodegeneration. J Clin Investig. 2020;130:4954\u201368.","journal-title":"J Clin Investig"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1523\/JNEUROSCI.2590-20.2021","article-title":"Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons","volume":"41","author":"Oakley DH","year":"2021","unstructured":"Oakley DH, Klickstein N, Commins C, Chung M, Dujardin S, Bennett RE, Hyman BT, Frosch MP. Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. J Neurosci. 2021;41:4335.","journal-title":"J Neurosci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41583-018-0113-1","article-title":"Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis","volume":"20","author":"Henstridge CM","year":"2019","unstructured":"Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci. 2019;20:94\u2013108.","journal-title":"Nat Rev Neurosci"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1096\/fj.201600756R","article-title":"Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease","volume":"30","author":"Goetzl EJ","year":"2016","unstructured":"Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, Schwartz JB, Miller BL. Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2016;30:3853\u20139.","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ajpath.2011.05.047","article-title":"Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease","volume":"179","author":"Serrano-Pozo A","year":"2011","unstructured":"Serrano-Pozo A, Mielke ML, G\u00f3mez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol. 2011;179:1373\u201384.","journal-title":"Am J Pathol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acsmedchemlett.2c00404","article-title":"Effects of 6-Aminonicotinic Acid Esters on the Reprogrammed Epigenetic State of Distant Metastatic Pancreatic Carcinoma","volume":"13","author":"Gao R-D","year":"2022","unstructured":"Gao R-D, Maeda M, Tallon C, Feinberg AP, Slusher BS, Tsukamoto T. Effects of 6-Aminonicotinic Acid Esters on the Reprogrammed Epigenetic State of Distant Metastatic Pancreatic Carcinoma. ACS Med Chem Lett. 2022;13:1892\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1038\/tp.2016.254","article-title":"Hippocampal encoding of interoceptive context during fear conditioning","volume":"7","author":"Yoo SW","year":"2017","unstructured":"Yoo SW, Bae M, Tovar-Y-Romo LB, Haughey NJ. Hippocampal encoding of interoceptive context during fear conditioning. Translational psychiatry. 2017;7:e991\u20131.","journal-title":"Translational psychiatry"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1471-4159.2009.06038.x","article-title":"Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors","volume":"109","author":"Wheeler D","year":"2009","unstructured":"Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, Mattson MP, Geiger JD, Haughey NJ. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem. 2009;109:1237\u201349.","journal-title":"J Neurochem"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"17715","DOI":"10.1038\/s41598-018-36144-2","article-title":"Slusher, DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation","volume":"8","author":"Rojas C","year":"2018","unstructured":"Rojas C, Barnaeva E, Thomas AG, Hu X, Southall N, Marugan J, Chaudhuri AD, Yoo S-W, Hin N, Stepanek O, Wu Y, Zimmermann SC, Gadiano AG, Tsukamoto T, Rais R, Haughey N, Ferrer M. Slusher, DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. Sci Rep. 2018;8:17715.","journal-title":"Sci Rep"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e0124481","DOI":"10.1371\/journal.pone.0124481","article-title":"Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties","volume":"10","author":"Figuera-Losada M","year":"2015","unstructured":"Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, Bandaru VV, Yoo SW, Westwood NJ, Rogers GW, McArthur JC, Haughey NJ, Slusher BS, Rojas C. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties. PLoS ONE. 2015;10:e0124481.","journal-title":"PLoS ONE"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh EG","year":"1959","unstructured":"Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911\u20137.","journal-title":"Can J Biochem Physiol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"105734","DOI":"10.1016\/j.nbd.2022.105734","article-title":"Slusher, Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV","volume":"169","author":"Zhu X","year":"2022","unstructured":"Zhu X, Hollinger KR, Huang Y, Borjabad A, Kim BH, Arab T, Thomas AG, Moniruzzaman M, Lovell L, Turchinovich A, Witwer KW, Volsky DJ, Haughey NJ. Slusher, Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV. Neurobiol Dis. 2022;169:105734.","journal-title":"Neurobiol Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.10828","article-title":"Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia","volume":"55","author":"Haughey NJ","year":"2004","unstructured":"Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, Turchan J, Nath A, Mattson MP. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol. 2004;55:257\u201367.","journal-title":"Ann Neurol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1212\/01.wnl.0000260610.79853.47","article-title":"Associative and predictive biomarkers of dementia in HIV-1-infected patients","volume":"68","author":"Bandaru VV","year":"2007","unstructured":"Bandaru VV, McArthur JC, Sacktor N, Cutler RG, Knapp EL, Mattson MP, Haughey NJ. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology. 2007;68:1481\u20137.","journal-title":"Neurology"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-1-4939-7816-8_26","volume-title":"Amyloid Proteins: Methods and Protocols","author":"Sahara N","year":"2018","unstructured":"Sahara N, Kimura T. In: Sigurdsson EM, Calero M, Gasset M, editors. Amyloid Proteins: Methods and Protocols. New York, NY: Springer New York; 2018. pp. 435\u201345."},{"key":"ref63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/ntno.63158","article-title":"Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis","volume":"6","author":"Hollinger KR","year":"2022","unstructured":"Hollinger KR, Sharma A, Tallon C, Lovell L, Thomas AG, Zhu X, Wiseman R, Wu Y, Kambhampati SP, Liaw K, Sharma R, Rojas C, Rais R, Kannan S, Kannan RM, Slusher BS. Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis. Nanotheranostics. 2022;6:126\u201342.","journal-title":"Nanotheranostics"},{"year":"2021","author":"Delgado-Peraza F","key":"ref64","unstructured":"Delgado-Peraza F, Nogueras-Ortiz CJ, Volpert O, Liu D, Goetzl EJ, Mattson MP, Greig NH, Eitan E, Kapogiannis D. Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease. Cells 10, (2021)."},{"key":"ref65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12964-023-01045-z","article-title":"A novel isolation method for spontaneously released extracellular vesicles from brain tissue and its implications for stress-driven brain pathology","volume":"21","author":"Gomes PA","year":"2023","unstructured":"Gomes PA, Bodo C, Nogueras-Ortiz C, Samiotaki M, Chen M, Soares-Cunha C, Silva JM, Coimbra B, Stamatakis G, Santos L, Panayotou G, Tzouanou F, Waites CL, Gatsogiannis C, Sousa N, Kapogiannis D, Costa-Silva B, Sotiropoulos I. A novel isolation method for spontaneously released extracellular vesicles from brain tissue and its implications for stress-driven brain pathology. Cell Commun Signal. 2023;21:35. SUPPLEMENTARY REFERENCES.","journal-title":"Cell Commun Signal"},{"year":"2021","author":"Biogen","key":"ref66","unstructured":"Biogen. Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer\u2019s Disease at AAIC 2021. 2021."},{"key":"ref67","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos KI","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. Ageing Res Rev. 2021;68:101339.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"ref68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak H","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"ref69","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele R","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"ref70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.febslet.2011.11.022","article-title":"Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles","volume":"586","author":"Simon D","year":"2012","unstructured":"Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012;586(1):47\u201354.","journal-title":"FEBS Lett"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","article-title":"Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review","volume":"76","author":"Gibbons GS","year":"2019","unstructured":"Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review. JAMA Neurol. 2019;76(1):101\u20138.","journal-title":"JAMA Neurol"},{"issue":"3","key":"ref72","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acn3.176","article-title":"Anti-tau antibody reduces insoluble tau and decreases brain atrophy","volume":"2","author":"Yanamandra K","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278\u201388.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","article-title":"Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating","volume":"20","author":"Mullard A","year":"2021","unstructured":"Mullard A. Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov. 2021;20(1):3\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"ref74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1673-5374.340409","article-title":"Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-beta story","volume":"18","author":"Imbimbo BP","year":"2023","unstructured":"Imbimbo BP, Balducci C, Ippati S, Watling M. Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-beta story. Neural Regen Res. 2023;18(1):117\u20138.","journal-title":"Neural Regen Res"},{"issue":"6","key":"ref75","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1074\/jbc.M111.277061","article-title":"Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease","volume":"287","author":"Saman S","year":"2012","unstructured":"Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287(6):3842\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"ref76","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/brain\/awaa376","article-title":"Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons","volume":"144","author":"Ruan Z","year":"2021","unstructured":"Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N, et al. Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain. 2021;144(1):288\u2013309.","journal-title":"Brain"},{"issue":"5867","key":"ref77","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic K","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244\u20137.","journal-title":"Science"},{"key":"ref78","article-title":"Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases","author":"Tallon C","year":"2021","unstructured":"Tallon C, Hollinger KR, Pal A, Bell BJ, Rais R, Tsukamoto T et al. Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. Drug Discovery Today. 2021.","journal-title":"Drug Discovery Today"},{"issue":"13","key":"ref79","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/jnr.22438","article-title":"Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice","volume":"88","author":"Tabatadze N","year":"2010","unstructured":"Tabatadze N, Savonenko A, Song H, Bandaru VV, Chu M, Haughey NJ. Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res. 2010;88(13):2940\u201351.","journal-title":"J Neurosci Res"},{"issue":"10","key":"ref80","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102066","article-title":"Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice","volume":"14","author":"Tallon C","year":"2022","unstructured":"Tallon C, Bell BJ, Sharma A, Pal A, Malvankar MM, Thomas AG et al. Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice. Pharmaceutics. 2022;14(10).","journal-title":"Pharmaceutics"},{"issue":"11","key":"ref81","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","article-title":"Depletion of microglia and inhibition of exosome synthesis halt tau propagation","volume":"18","author":"Asai H","year":"2015","unstructured":"Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584\u201393.","journal-title":"Nat Neurosci"},{"key":"ref82","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.0c00311","article-title":"Dual Neutral Sphingomyelinase-2\/Acetylcholinesterase Inhibitors for the treatment of Alzheimer\u2019s disease","author":"Bilousova T","year":"2020","unstructured":"Bilousova T, Simmons BJ, Knapp RR, Elias CJ, Campagna J, Melnik M et al. Dual Neutral Sphingomyelinase-2\/Acetylcholinesterase Inhibitors for the treatment of Alzheimer\u2019s disease. ACS Chem Biol. 2020.","journal-title":"ACS Chem Biol"},{"issue":"19","key":"ref83","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1111\/bph.14789","article-title":"A novel and potent brain penetrant inhibitor of extracellular vesicle release","volume":"176","author":"Rojas C","year":"2019","unstructured":"Rojas C, Sala M, Thomas AG, Datta Chaudhuri A, Yoo SW, Li Z, et al. A novel and potent brain penetrant inhibitor of extracellular vesicle release. Br J Pharmacol. 2019;176(19):3857\u201370.","journal-title":"Br J Pharmacol"},{"key":"ref84","article-title":"Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer disease","author":"Sala M","year":"2020","unstructured":"Sala M, Hollinger KR, Thomas AG, Dash RP, Tallon C, Veeravalli V et al. Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer disease. J Med Chem. 2020.","journal-title":"J Med Chem"},{"issue":"3","key":"ref85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-2011-111202","article-title":"Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases","volume":"29","author":"Filippov V","year":"2012","unstructured":"Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, et al. Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis. 2012;29(3):537\u201347.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"ref86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-200964","article-title":"Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia","volume":"81","author":"Teitsdottir UD","year":"2021","unstructured":"Teitsdottir UD, Halldorsson S, Rolfsson O, Lund SH, Jonsdottir MK, Snaedal J, et al. Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. J Alzheimers Dis. 2021;81(1):231\u201344.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"ref87","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jalz.2010.03.014","article-title":"Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss","volume":"6","author":"Mielke MM","year":"2010","unstructured":"Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC, et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010;6(5):378\u201385.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"ref88","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3233\/JAD-160925","article-title":"The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging","volume":"60","author":"Mielke MM","year":"2017","unstructured":"Mielke MM, Haughey NJ, Han D, An Y, Bandaru VVR, Lyketsos CG, et al. The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. J Alzheimers Dis. 2017;60(3):819\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"ref89","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.neuroscience.2004.08.056","article-title":"Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis","volume":"130","author":"Satoi H","year":"2005","unstructured":"Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M, et al. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience. 2005;130(3):657\u201366.","journal-title":"Neuroscience"},{"issue":"4","key":"ref90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.10312","article-title":"Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis","volume":"52","author":"Cutler RG","year":"2002","unstructured":"Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448\u201357.","journal-title":"Ann Neurol"},{"issue":"4","key":"ref91","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry RD","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"8925","key":"ref92","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","article-title":"Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease","volume":"344","author":"West MJ","year":"1994","unstructured":"West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. The Lancet. 1994;344(8925):769\u201372.","journal-title":"The Lancet"},{"issue":"3","key":"ref93","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/STROKEAHA.111.636498","article-title":"Hippocampal Neuronal Atrophy and Cognitive Function in Delayed Poststroke and Aging-Related Dementias","volume":"43","author":"Gemmell E","year":"2012","unstructured":"Gemmell E, Bosomworth H, Allan L, Hall R, Khundakar A, Oakley AE, et al. Hippocampal Neuronal Atrophy and Cognitive Function in Delayed Poststroke and Aging-Related Dementias. Stroke. 2012;43(3):808\u201314.","journal-title":"Stroke"},{"issue":"12","key":"ref94","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acsmedchemlett.2c00404","article-title":"Effects of 6-Aminonicotinic Acid Esters on the Reprogrammed Epigenetic State of Distant Metastatic Pancreatic Carcinoma","volume":"13","author":"Gao R-D","year":"2022","unstructured":"Gao R-D, Maeda M, Tallon C, Feinberg AP, Slusher BS, Tsukamoto T. Effects of 6-Aminonicotinic Acid Esters on the Reprogrammed Epigenetic State of Distant Metastatic Pancreatic Carcinoma. ACS Med Chem Lett. 2022;13(12):1892\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"ref95","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1038\/tp.2016.254","article-title":"Hippocampal encoding of interoceptive context during fear conditioning","volume":"7","author":"Yoo SW","year":"2017","unstructured":"Yoo SW, Bae M, Tovar-Y-Romo LB, Haughey NJ. Hippocampal encoding of interoceptive context during fear conditioning. Translational psychiatry. 2017;7(1):e991\u2013e.","journal-title":"Translational psychiatry"},{"issue":"5","key":"ref96","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1471-4159.2009.06038.x","article-title":"Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors","volume":"109","author":"Wheeler D","year":"2009","unstructured":"Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, et al. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem. 2009;109(5):1237\u201349.","journal-title":"J Neurochem"},{"issue":"19","key":"ref97","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/hmg\/ddz151","article-title":"Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy","volume":"28","author":"Koller EJ","year":"2019","unstructured":"Koller EJ, De La Cruz G, Machula E, Ibanez T, Lin KR, Williams W-L. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Hum Mol Genet. 2019;28(19):3255\u201369.","journal-title":"Hum Mol Genet"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"114796","DOI":"10.1016\/j.bcp.2021.114796","article-title":"Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury","author":"Tallon C","year":"2021","unstructured":"Tallon C, Picciolini S, Yoo S-W, Thomas AG, Pal A, Alt J et al. Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury. Biochem Pharmacol. 2021:114796.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"ref99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama Y","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337\u201351.","journal-title":"Neuron"},{"issue":"1","key":"ref100","doi-asserted-by":"crossref","first-page":"17715","DOI":"10.1038\/s41598-018-36144-2","article-title":"DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation","volume":"8","author":"Rojas C","year":"2018","unstructured":"Rojas C, Barnaeva E, Thomas AG, Hu X, Southall N, Marugan J, et al. DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. Sci Rep. 2018;8(1):17715.","journal-title":"Sci Rep"},{"issue":"5","key":"ref101","doi-asserted-by":"crossref","first-page":"e0124481","DOI":"10.1371\/journal.pone.0124481","article-title":"Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties","volume":"10","author":"Figuera-Losada M","year":"2015","unstructured":"Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, Bandaru VV, Yoo SW, et al. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties. PLoS ONE. 2015;10(5):e0124481.","journal-title":"PLoS ONE"},{"issue":"8","key":"ref102","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/o59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh EG","year":"1959","unstructured":"Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911\u20137.","journal-title":"Can J Biochem Physiol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"105734","DOI":"10.1016\/j.nbd.2022.105734","article-title":"Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV","volume":"169","author":"Zhu X","year":"2022","unstructured":"Zhu X, Hollinger KR, Huang Y, Borjabad A, Kim BH, Arab T, et al. Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV. Neurobiol Dis. 2022;169:105734.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"ref104","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.10828","article-title":"Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia","volume":"55","author":"Haughey NJ","year":"2004","unstructured":"Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol. 2004;55(2):257\u201367.","journal-title":"Ann Neurol"},{"issue":"18","key":"ref105","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1212\/01.wnl.0000260610.79853.47","article-title":"Associative and predictive biomarkers of dementia in HIV-1-infected patients","volume":"68","author":"Bandaru VV","year":"2007","unstructured":"Bandaru VV, McArthur JC, Sacktor N, Cutler RG, Knapp EL, Mattson MP, et al. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology. 2007;68(18):1481\u20137.","journal-title":"Neurology"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-1-4939-7816-8_26","volume-title":"Amyloid Proteins: Methods and Protocols","author":"Sahara N","year":"2018","unstructured":"Sahara N, Kimura T. Biochemical Properties of Pathology-Related Tau Species in Tauopathy Brains: An Extraction Protocol for Tau Oligomers and Aggregates. In: Sigurdsson EM, Calero M, Gasset M, editors. Amyloid Proteins: Methods and Protocols. New York, NY: Springer New York; 2018. pp. 435\u201345."},{"issue":"2","key":"ref107","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/ntno.63158","article-title":"Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis","volume":"6","author":"Hollinger KR","year":"2022","unstructured":"Hollinger KR, Sharma A, Tallon C, Lovell L, Thomas AG, Zhu X, et al. Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis. Nanotheranostics. 2022;6(2):126\u201342.","journal-title":"Nanotheranostics"},{"issue":"9","key":"ref108","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1172\/JCI138179","article-title":"Impact of TREM2R47H variant on tau pathology\u2013induced gliosis and neurodegeneration","volume":"130","author":"Gratuze M","year":"2020","unstructured":"Gratuze M, Leyns CEG, Sauerbeck AD, St-Pierre M-K, Xiong M, Kim N, et al. Impact of TREM2R47H variant on tau pathology\u2013induced gliosis and neurodegeneration. J Clin Investig. 2020;130(9):4954\u201368.","journal-title":"J Clin Investig"},{"issue":"5","key":"ref109","doi-asserted-by":"crossref","DOI":"10.3390\/cells10050993","article-title":"Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease","volume":"10","author":"Delgado-Peraza F","year":"2021","unstructured":"Delgado-Peraza F, Nogueras-Ortiz CJ, Volpert O, Liu D, Goetzl EJ, Mattson MP et al. Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease. Cells. 2021;10(5).","journal-title":"Cells"},{"issue":"1","key":"ref110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12964-023-01045-z","article-title":"A novel isolation method for spontaneously released extracellular vesicles from brain tissue and its implications for stress-driven brain pathology","volume":"21","author":"Gomes PA","year":"2023","unstructured":"Gomes PA, Bodo C, Nogueras-Ortiz C, Samiotaki M, Chen M, Soares-Cunha C, et al. A novel isolation method for spontaneously released extracellular vesicles from brain tissue and its implications for stress-driven brain pathology. Cell Commun Signal. 2023;21(1):35.","journal-title":"Cell Commun Signal"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neurobiolaging.2021.09.006","article-title":"Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy","volume":"109","author":"Patel H","year":"2022","unstructured":"Patel H, Martinez P, Perkins A, Taylor X, Jury N, McKinzie D, et al. Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol Aging. 2022;109:52\u201363.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"ref112","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/gb-2013-14-7-r82","article-title":"A comparative phenotypic and genomic analysis of C57BL\/6J and C57BL\/6N mouse strains","volume":"14","author":"Simon MM","year":"2013","unstructured":"Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, et al. A comparative phenotypic and genomic analysis of C57BL\/6J and C57BL\/6N mouse strains. Genome Biol. 2013;14(7):R82.","journal-title":"Genome Biol"},{"issue":"4","key":"ref113","first-page":"375","article-title":"Clinical Chemistry Reference Intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ Mice (Mus musculus)","volume":"55","author":"Otto GP","year":"2016","unstructured":"Otto GP, Rathkolb B, Oestereicher MA, Lengger CJ, Moerth C, Micklich K, et al. Clinical Chemistry Reference Intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ Mice (Mus musculus). J Am Association Lab Anim Science: JAALAS. 2016;55(4):375\u201386.","journal-title":"J Am Association Lab Anim Science: JAALAS"},{"author":"Laboratory TJ","key":"ref114","unstructured":"Laboratory TJ. Physiological Data Summary - C57BL\/6J (000664) [Available from: https:\/\/jackson.jax.org\/rs\/444-BUH-304\/images\/physiological_data_000664.pdf."},{"key":"ref115","unstructured":"Charles River Larboratories International I. C57BL\/6 Mice Datasheet 2019 [Available from: https:\/\/www.criver.com\/sites\/default\/files\/resources\/C57BL6MouseModelInformationSheet.pdf."},{"author":"Taconic Biosciences I","key":"ref116","unstructured":"Taconic Biosciences I. Automated Clinical Chemistry Analysis (ACCA) 2011 [updated 12\/19\/2011. 12\/19\/2011:[Available from: https:\/\/www.taconic.com\/phenotypic-data\/automated-clinical-chemistry-analysis\/."},{"issue":"6","key":"ref117","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","article-title":"Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study","volume":"11","author":"Fiandaca MS","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 2015;11(6):600\u20137e1.","journal-title":"Alzheimers Dement"},{"key":"ref118","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2462","article-title":"Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of AgingAssociation of Extracellular Vesicle Biomarkers With Alzheimer DiseaseAssociation of Extracellular Vesicle Biomarkers With Alzheimer Disease","author":"Kapogiannis D","year":"2019","unstructured":"Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD et al. Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of AgingAssociation of Extracellular Vesicle Biomarkers With Alzheimer DiseaseAssociation of Extracellular Vesicle Biomarkers With Alzheimer Disease. JAMA Neurol. 2019.","journal-title":"JAMA Neurol"},{"key":"ref119","volume-title":"Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer\u2019s Disease","author":"Bell BJ","year":"2020","unstructured":"Bell BJ, Malvankar MM, Tallon C, Slusher BS. Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer\u2019s Disease. ACS Chemical Neuroscience; 2020."},{"issue":"5867","key":"ref120","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes","volume":"319","author":"Trajkovic K","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes. Science. 2008;319(5867):1244\u20137.","journal-title":"Science"},{"issue":"8","key":"ref121","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081956","article-title":"Diverse Roles of Ceramide in the Progression and Pathogenesis of Alzheimer's Disease","volume":"10","author":"Chowdhury MR","year":"2022","unstructured":"Chowdhury MR, Jin HK, Bae JS. Diverse Roles of Ceramide in the Progression and Pathogenesis of Alzheimer's Disease. Biomedicines. 2022;10(8).","journal-title":"Biomedicines"},{"issue":"1","key":"ref122","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","article-title":"Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia","volume":"141","author":"Lowe VJ","year":"2018","unstructured":"Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain. 2018;141(1):271\u201387.","journal-title":"Brain"},{"issue":"Pt 5","key":"ref123","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele R","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551\u201367.","journal-title":"Brain"},{"key":"ref124"},{"issue":"374","key":"ref125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos SL","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374).","journal-title":"Sci Transl Med"},{"issue":"43","key":"ref126","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1073\/pnas.1710311114","article-title":"TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy","volume":"114","author":"Leyns CEG","year":"2017","unstructured":"Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114(43):11524\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"ref127","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1523\/JNEUROSCI.2590-20.2021","article-title":"Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons","volume":"41","author":"Oakley DH","year":"2021","unstructured":"Oakley DH, Klickstein N, Commins C, Chung M, Dujardin S, Bennett RE, et al. Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. J Neurosci. 2021;41(19):4335.","journal-title":"J Neurosci"},{"issue":"2","key":"ref128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41583-018-0113-1","article-title":"Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis","volume":"20","author":"Henstridge CM","year":"2019","unstructured":"Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci. 2019;20(2):94\u2013108.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"ref129","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1096\/fj.201600756R","article-title":"Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease","volume":"30","author":"Goetzl EJ","year":"2016","unstructured":"Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, et al. Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2016;30(11):3853\u20139.","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"issue":"3","key":"ref130","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ajpath.2011.05.047","article-title":"Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease","volume":"179","author":"Serrano-Pozo A","year":"2011","unstructured":"Serrano-Pozo A, Mielke ML, G\u00f3mez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol. 2011;179(3):1373\u201384.","journal-title":"Am J Pathol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3131295\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3131295\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T15:42:54Z","timestamp":1702309374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3131295\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":130,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3131295\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s40035-023-00383-9","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,7,18]]},"subtype":"preprint"}}